{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:10:07Z","timestamp":1788487807439,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T00:00:00Z","timestamp":1552953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T00:00:00Z","timestamp":1552953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"U.S. Department of Health &amp; Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS079060"],"award-info":[{"award-number":["NS079060"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI106705"],"award-info":[{"award-number":["AI106705"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gift from Alloplex Biotherapeutics Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Advances in biotechnology have led to the development of a number of biological therapies for the treatment of diverse human diseases. Since these products may contain or are made using human or animal (e.g. cattle) derived materials, it is crucial to test their safety by ensuring the absence of infectious agents; specifically prions, which are highly resilient to elimination and produce fatal diseases in humans. Many cases of iatrogenic Creutzfeldt-Jakob disease have been caused by the use of biological materials (e.g. human growth hormone) contaminated with prions. For this reason, it is important to screen cells and biological materials for the presence of prions. Here we show the utility of the Protein Misfolding Cyclic Amplification (PMCA) technology as a screening tool for the presence of human (vCJD) and bovine (BSE) prions in a human cell therapy product candidate. First, we demonstrated the sensitivity of PMCA to detect a single cell infected with prions. For these experiments, we used RKM7 cells chronically infected with murine RML prions. Serial dilutions of an infected cell culture showed that PMCA enabled prion amplification from a sample comprised of only one cell. Next, we determined that PMCA performance was robust and uncompromised by the spiking of large quantities of uninfected cells into the reaction. Finally, to demonstrate the practical application of this technology, we analyzed a human cell line being developed for therapeutic use and found it to be PMCA-negative for vCJD and BSE prions. Our findings demonstrate that the PMCA technology has unparalleled sensitivity and specificity for the detection of prions, making it an ideal quality control procedure in the production of biological therapeutics.<\/jats:p>","DOI":"10.1038\/s41598-019-41055-x","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T21:35:28Z","timestamp":1553031328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Application of PMCA to screen for prion infection in a human cell line used to produce biological therapeutics"],"prefix":"10.1038","volume":"9","author":[{"given":"Adam","family":"Lyon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Mays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Borriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn C.","family":"Telling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Pritzkow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,19]]},"reference":[{"key":"41055_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.7326\/0003-4819-157-1-201206190-00429","volume":"157","author":"JL Carson","year":"2012","unstructured":"Carson, J. L. et al. Red blood cell transfusion: a clinical practice guideline from the AABB*. Ann. Intern. Med. 157, 49\u201358 (2012).","journal-title":"Ann. Intern. Med."},{"key":"41055_CR2","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/stem.2538","volume":"35","author":"CS Cox","year":"2017","unstructured":"Cox, C. S. et al. Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells. Stem Cells 35, 1065\u20131079 (2017).","journal-title":"Stem Cells"},{"key":"41055_CR3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1161\/STROKEAHA.116.012995","volume":"47","author":"GK Steinberg","year":"2016","unstructured":"Steinberg, G. K. et al. Clinical Outcomes of Transplanted Modified Bone Marrow\u2013Derived Mesenchymal Stem Cells in Stroke. Stroke 47, 1817\u20131824 (2016).","journal-title":"Stroke"},{"key":"41055_CR4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2174\/1567205013666160314145347","volume":"14","author":"P Bali","year":"2017","unstructured":"Bali, P., Lahiri, D. K., Banik, A., Nehru, B. & Anand, A. Potential for Stem Cells Therapy in Alzheimer\u2019s Disease: Do Neurotrophic Factors Play Critical Role? Curr. Alzheimer Res. 14, 208\u2013220 (2017).","journal-title":"Curr. Alzheimer Res."},{"key":"41055_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1590\/s1980-5764-2016dn1004006","volume":"10","author":"MS Haddad","year":"2016","unstructured":"Haddad, M. S., Wenceslau, C. V., Pompeia, C. & Kerkis, I. Cell-based technologies for Huntington\u2019s disease. Dement. Neuropsychol. 10, 287\u2013295 (2016).","journal-title":"Dement. Neuropsychol."},{"key":"41055_CR6","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1177\/0963689717735411","volume":"26","author":"T Yasuhara","year":"2017","unstructured":"Yasuhara, T., Kameda, M., Sasaki, T., Tajiri, N. & Date, I. Cell Therapy for Parkinson\u2019s Disease. Cell Transplant. 26, 1551\u20131559 (2017).","journal-title":"Cell Transplant."},{"key":"41055_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.blre.2015.07.004","volume":"30","author":"G Di Minno","year":"2016","unstructured":"Di Minno, G. et al. Current concepts in the prevention of pathogen transmission via blood\/plasma-derived products for bleeding disorders. Blood Rev. 30, 35\u201348 (2016).","journal-title":"Blood Rev."},{"key":"41055_CR8","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1152\/physrev.00006.2009","volume":"89","author":"A Aguzzi","year":"2009","unstructured":"Aguzzi, A. & Calella, A. M. Prions: protein aggregation and infectious diseases. Physiol. Rev. 89, 1105\u201352 (2009).","journal-title":"Physiol. Rev."},{"key":"41055_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.tibs.2010.11.001","volume":"36","author":"C Soto","year":"2011","unstructured":"Soto, C. Prion hypothesis: the end of the controversy? Trends Biochem. Sci. 36, 151\u2013158 (2011).","journal-title":"Trends Biochem. Sci."},{"key":"41055_CR10","doi-asserted-by":"publisher","first-page":"13363","DOI":"10.1073\/pnas.95.23.13363","volume":"95","author":"SB Prusiner","year":"1998","unstructured":"Prusiner, S. B. Prions. Proc. Natl. Acad. Sci. USA 95, 13363\u201383 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"41055_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/B978-0-12-802395-2.00028-6","volume":"145","author":"JW Ironside","year":"2018","unstructured":"Ironside, J. W., Ritchie, D. L. & Head, M. W. Prion diseases. In Handbook of clinical neurology 145, 393\u2013403 (2018).","journal-title":"In Handbook of clinical neurology"},{"key":"41055_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S0140-6736(99)05128-4","volume":"354","author":"J Collinge","year":"1999","unstructured":"Collinge, J. Variant Creutzfeldt-Jakob disease. Lancet (London, England) 354, 317\u201323 (1999).","journal-title":"Lancet (London, England)"},{"key":"41055_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.1440-1789.2009.01023.x","volume":"29","author":"T Hamaguchi","year":"2009","unstructured":"Hamaguchi, T. et al. The risk of iatrogenic Creutzfeldt-Jakob disease through medical and surgical procedures. Neuropathology 29, 625\u201331 (2009).","journal-title":"Neuropathology"},{"key":"41055_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1053\/tvjl.1999.0406","volume":"159","author":"DM Taylor","year":"2000","unstructured":"Taylor, D. M. Inactivation of Transmissible Degenerative Encephalopathy Agents: A Review. Vet. J. 159, 10\u201317 (2000).","journal-title":"Vet. J."},{"key":"41055_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/bmb\/66.1.161","volume":"66","author":"AF Hill","year":"2003","unstructured":"Hill, A. F. & Collinge, J. Subclinical prion infection in humans and animals. Br. Med. Bull. 66, 161\u2013170 (2003).","journal-title":"Br. Med. Bull."},{"key":"41055_CR16","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/nrmicro1003","volume":"2","author":"C Soto","year":"2004","unstructured":"Soto, C. Diagnosing prion diseases: needs, challenges and hopes. Nat. Rev. Microbiol. 2, 809\u2013819 (2004).","journal-title":"Nat. Rev. Microbiol."},{"key":"41055_CR17","unstructured":"World Health Organization. Screening Donated Blood for Transfussion-Transmissible Infections: Recomendation (2009)."},{"key":"41055_CR18","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/35081095","volume":"411","author":"GP Saborio","year":"2001","unstructured":"Saborio, G. P., Permanne, B. & Soto, C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 411, 810\u20133 (2001).","journal-title":"Nature"},{"key":"41055_CR19","doi-asserted-by":"publisher","first-page":"370ra183","DOI":"10.1126\/scitranslmed.aaf6188","volume":"8","author":"L Concha-Marambio","year":"2016","unstructured":"Concha-Marambio, L. et al. Detection of prions in blood from patients with variant Creutzfeldt-Jakob disease. Sci. Transl. Med. 8, 370ra183\u2013370ra183 (2016).","journal-title":"Sci. Transl. Med."},{"key":"41055_CR20","doi-asserted-by":"publisher","first-page":"370ra182","DOI":"10.1126\/scitranslmed.aag1257","volume":"8","author":"D Bougard","year":"2016","unstructured":"Bougard, D. et al. Detection of prions in the plasma of presymptomatic and symptomatic patients with variant Creutzfeldt-Jakob disease. Sci. Transl. Med. 8, 370ra182\u2013370ra182 (2016).","journal-title":"Sci. Transl. Med."},{"key":"41055_CR21","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1056\/NEJMoa1404401","volume":"371","author":"F Moda","year":"2014","unstructured":"Moda, F. et al. Prions in the Urine of Patients with Variant Creutzfeldt\u2013Jakob Disease. N. Engl. J. Med. 371, 530\u2013539 (2014).","journal-title":"N. Engl. J. Med."},{"key":"41055_CR22","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/nprot.2012.067","volume":"7","author":"R Morales","year":"2012","unstructured":"Morales, R., Duran-Aniotz, C., Diaz-Espinoza, R., Camacho, M. V. & Soto, C. Protein misfolding cyclic amplification of infectious prions. Nat. Protoc. 7, 1397\u2013409 (2012).","journal-title":"Nat. Protoc."},{"key":"41055_CR23","doi-asserted-by":"publisher","first-page":"35245","DOI":"10.1074\/jbc.M603964200","volume":"281","author":"P Sa\u00e1","year":"2006","unstructured":"Sa\u00e1, P., Castilla, J. & Soto, C. Ultra-efficient Replication of Infectious Prions by Automated Protein Misfolding Cyclic Amplification. J. Biol. Chem. 281, 35245\u201335252 (2006).","journal-title":"J. Biol. Chem."},{"key":"41055_CR24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nmeth.1465","volume":"7","author":"B Chen","year":"2010","unstructured":"Chen, B., Morales, R., Barria, M. A. & Soto, C. Estimating prion concentration in fluids and tissues by quantitative PMCA. Nat. Methods 7, 519\u2013520 (2010).","journal-title":"Nat. Methods"},{"key":"41055_CR25","doi-asserted-by":"publisher","first-page":"e18047","DOI":"10.1371\/journal.pone.0018047","volume":"6","author":"CE Mays","year":"2011","unstructured":"Mays, C. E. et al. In vitro amplification of misfolded prion protein using lysate of cultured cells. PLoS One 6, e18047 (2011).","journal-title":"PLoS One"},{"key":"41055_CR26","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.3171\/2016.5.FOCUS15126","volume":"41","author":"DJ Bonda","year":"2016","unstructured":"Bonda, D. J. et al. Human prion diseases: surgical lessons learned from iatrogenic prion transmission. Neurosurg. Focus 41, E10 (2016).","journal-title":"Neurosurg. Focus"},{"key":"41055_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/978-1-4939-7244-9_14","volume":"1658","author":"CD Orr\u00f9","year":"2017","unstructured":"Orr\u00f9, C. D. et al. RT-QuIC Assays for Prion Disease Detection and Diagnostics. in. Methods in molecular biology (Clifton, N.J.) 1658, 185\u2013203 (2017).","journal-title":"Methods in molecular biology (Clifton, N.J.)"},{"key":"41055_CR28","doi-asserted-by":"publisher","first-page":"e1004202","DOI":"10.1371\/journal.ppat.1004202","volume":"10","author":"C Lacroux","year":"2014","unstructured":"Lacroux, C. et al. Preclinical detection of variant CJD and BSE prions in blood. PLoS Pathog. 10, e1004202 (2014).","journal-title":"PLoS Pathog."},{"key":"41055_CR29","doi-asserted-by":"publisher","first-page":"f5675","DOI":"10.1136\/bmj.f5675","volume":"347","author":"ON Gill","year":"2013","unstructured":"Gill, O. N. et al. Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey. BMJ 347, f5675\u2013f5675 (2013).","journal-title":"BMJ"},{"key":"41055_CR30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S0140-6736(04)15486-X","volume":"363","author":"C Llewelyn","year":"2004","unstructured":"Llewelyn, C. et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363, 417\u2013421 (2004).","journal-title":"Lancet"},{"key":"41055_CR31","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S0140-6736(04)16811-6","volume":"364","author":"AH Peden","year":"2004","unstructured":"Peden, A. H., Head, M. W., Diane, L. R., Jeanne, E. B. & James, W. I. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364, 527\u2013529 (2004).","journal-title":"Lancet"},{"key":"41055_CR32","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1016\/S0140-6736(06)69835-8","volume":"368","author":"SJ Wroe","year":"2006","unstructured":"Wroe, S. J. et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 368, 2061\u20132067 (2006).","journal-title":"Lancet"},{"key":"41055_CR33","doi-asserted-by":"publisher","first-page":"946","DOI":"10.3201\/eid2306.161734","volume":"23","author":"JY Douet","year":"2017","unstructured":"Douet, J. Y. et al. Distribution and Quantitative Estimates of Variant Creutzfeldt-Jakob Disease Prions in Tissues of Clinical and Asymptomatic Patients. Emerg. Infect. Dis. 23, 946\u2013956 (2017).","journal-title":"Emerg. Infect. Dis."},{"key":"41055_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-016-0143-8","volume":"5","author":"C Chen","year":"2016","unstructured":"Chen, C. & Dong, X.-P. Epidemiological characteristics of human prion diseases. Infect. Dis. poverty 5, 47 (2016).","journal-title":"Infect. Dis. poverty"},{"key":"41055_CR35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1146\/annurev-neuro-071714-033828","volume":"38","author":"LC Walker","year":"2015","unstructured":"Walker, L. C. & Jucker, M. Neurodegenerative diseases: expanding the prion concept. Annu. Rev. Neurosci. 38, 87\u2013103 (2015).","journal-title":"Annu. Rev. Neurosci."},{"key":"41055_CR36","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/s41593-018-0235-9","volume":"21","author":"C Soto","year":"2018","unstructured":"Soto, C. & Pritzkow, S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat. Neurosci. 21, 1332\u20131340 (2018).","journal-title":"Nat. Neurosci."},{"key":"41055_CR37","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1016\/j.celrep.2014.02.031","volume":"7","author":"N Salvadores","year":"2014","unstructured":"Salvadores, N., Shahnawaz, M., Scarpini, E., Tagliavini, F. & Soto, C. Detection of Misfolded Abeta Oligomers for Sensitive Biochemical Diagnosis of Alzheimer\u2019s Disease. Cell Rep. 7, 2061\u20132068 (2014).","journal-title":"Cell Rep."},{"key":"41055_CR38","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","volume":"74","author":"M Shahnawaz","year":"2017","unstructured":"Shahnawaz, M. et al. Development of a Biochemical Diagnosis of Parkinson Disease by Detection of alpha-Synuclein Misfolded Aggregates in Cerebrospinal Fluid. JAMA Neurol. 74, 163\u2013172 (2017).","journal-title":"JAMA Neurol."},{"key":"41055_CR39","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00401-017-1692-z","volume":"133","author":"E Saijo","year":"2017","unstructured":"Saijo, E. et al. Ultrasensitive and selective detection of 3-repeat tau seeding activity in Pick disease brain and cerebrospinal fluid. Acta Neuropathol. 133, 751\u2013765 (2017).","journal-title":"Acta Neuropathol."},{"key":"41055_CR40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-018-0508-2","volume":"6","author":"BR Groveman","year":"2018","unstructured":"Groveman, B. R. et al. Rapid and ultra-sensitive quantitation of disease-associated alpha-synuclein seeds in brain and cerebrospinal fluid by alphaSyn RT-QuIC. Acta Neuropathol. Commun. 6, 7 (2018).","journal-title":"Acta Neuropathol. Commun."},{"key":"41055_CR41","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/acn3.338","volume":"3","author":"G Fairfoul","year":"2016","unstructured":"Fairfoul, G. et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann. Clin. Transl. Neurol. 3, 812\u2013818 (2016).","journal-title":"Ann. Clin. Transl. Neurol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41055-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41055-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41055-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T07:45:27Z","timestamp":1671263127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41055-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,19]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["41055"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-41055-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,19]]},"assertion":[{"value":"2 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Soto is inventor on several patents related to the PMCA technology and is currently Founder, Chief Scientific Officer and Vice-President of Amprion Inc, a biotech company focusing on the commercial utilization of PMCA and RT-QuIC for prion diagnosis. Dr. Borriello is CEO and founder of Alloplex Biotherapeutics, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"4847"}}